Gene therapy developer Bluebird Bio said Monday that it has submitted a long-awaited application asking the Food and Drug Administration to approve its drug for sickle cell disease, setting up ...

Bluebird touts Zynteglo, Skysona launch progress as FDA decision on sickle cell therapy nears While struggling on the financial front, bluebird has one advantage in Lyfgenia’s favor.

Sickle cell patient Dominique Goodson, 38 and pregnant with her first child, said she would like to get a gene therapy a year or so after she gives birth in December, but she needs to make sure ...

GlobalData is the parent company of Pharmaceutical Technology. bluebird bio’s CEO Andrew Obenshain said: “Lovo-cel is the most deeply studied gene therapy in development for sickle cell ...

A 12-year-old boy has become the first patient in the U.S. to receive gene therapy for sickle cell disease, The New York Times reported Oct. 21. Kendric Cromer began treatment with Bluebird bio ...

With a dedicated focus on severe genetic diseases, bluebird has the largest and deepest ex-vivo gene therapy data set in the field, with industry-leading programs for sickle cell disease, β ...

Vertex Pharmaceuticals and bluebird bio have entered into an agreement with CMS to participate in a new Medicaid payment model for gene-based sickle cell anemia treatments, the agency announced ...

bluebird bio, Inc. ... LYFGENIA is a one-time gene therapy to treat sickle cell disease in individuals 12 years of age or older and a history of vaso-occlusive events (VOEs).

Gene therapy for sickle cell disease may help improve a major contributing factor to stroke risk in patients, reports a new ...

About 100,000 people in the United States have sickle cell disease. For the 20,000 or so with the most severe disease, gene therapy may be their only hope of living a normal life.

Some doctors told him he'd live with the disease forever, but Khaled Alsheebani never stopped believing treatments would advance one day.

Sickle cell patient Dominique Goodson, 38 and pregnant with her first child, said she would like to get a gene therapy a year or so after she gives birth in December, but she needs to make sure ...